Efficacy of etrasimod at Week 52 among patients with clinical response at Week 12 compared with the overall ulcerative colitis population: post hoc analysis of the phase 3 ELEVATE UC 52 trial

Author:

Siegmund B.12,Vermeire S.3,Sands B. E.4,Dubinsky M. C.5,Feagan B. G.67,Panaccione R.8,Jairath V.9,Yarur A.10,Chiorean M.11,Panés J.12,Goetsch M.13,Rabbat C. J.14,Shah P.15,Wu J.16,Ghosh S.17

Affiliation:

1. Charité – Universitätsmedizin Berlin, Med. Klinik für Gastroenterologie, Infektiologie, Rheumatologie, Berlin, Deutschland

2. Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Deutschland

3. University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgien

4. Icahn School of Medicine at Mount Sinai, Dr Henry D. Janowitz Division of Gastroenterology, New York, Vereinigte Staaten

5. Icahn School of Medicine at Mount Sinai, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, New York, Vereinigte Staaten

6. University of Western Ontario, Division of Gastroenterology, London Health Sciences Centre, London, Kanada

7. Alimentiv Inc., London, Kanada

8. University of Calgary, Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, Calgary, Kanada

9. University of Western Ontario, Division of Gastroenterology, Department of Medicine, London, Kanada

10. Cedars-Sinai Medical Center, Inflammatory Bowel Disease Center and Division of Gastroenterology and Hepatology, Los Angeles, Vereinigte Staaten

11. Swedish Medical Center, Division of Gastroenterology and Hepatology, IBD Center, Seattle, Vereinigte Staaten

12. Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Formerly Department of Gastroenterology, Barcelona, Spanien

13. Pfizer AG, Zürich, Schweiz

14. Pfizer Inc., New York, Vereinigte Staaten

15. Pfizer Inc., Collegeville, Vereinigte Staaten

16. Pfizer Inc., Groton, Vereinigte Staaten

17. University College Cork, College of Medicine and Health, APC Microbiome Ireland, Cork, Irland

Publisher

Georg Thieme Verlag

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3